Figure 5. Reduction of DENV3 viral burden in vivo by selected hmAbs.

AG129 mice were administered 50 mg hmAb (unless otherwise indicated) by intraperitoneal injection 24 hours prior to infection with 5×10⁶ plaque forming units (PFU) of DENV3 UNC3009. Virus titers were assessed 72 hours post-infection using quantitative RT-PCR of RNA isolated from the spleens of infected mice and are expressed as genome equivalents (GE) normalized to mg of GAPDH. Group 1 DENV-443 and Group 2 DENV-115, −290, and −419 hmAbs reduced DENV3 viral load compared to IgG isotype antibody. The number of mice in each treatment group are indicated, comprising 5 independent experiments in total, with at least 2 independent experiments performed for each hmAb. The limit of detection is 10⁴ GE/mg of GAPDH. Comparisons were performed using Kruskal-Wallis test with Dunn’s multiple comparisons (** p<0.005, *** p<0.0005, **** p<0.0001).